Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Pao

Showing results (31-40 of 202) with videos related to

Pageof 21
Sort By:
Genome Research|September 29, 2012
Translating genomic information into clinical medicine: lung cancer as a paradigmMia A Levy, Christine M Lovly, William Pao
Seminars in Cancer Biology|February 6, 2004
'Targeting' the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa) in non-small cell lung cancer (NSCLC)William Pao, Vincent A Miller, Mark G Kris
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 18, 2012
Effects of pharmacokinetic processes and varied dosing schedules on the dynamics of acquired resistance to erlotinib in EGFR-mutant lung cancerJasmine Foo, Juliann Chmielecki, William Pao, et al.
Nature Reviews. Clinical Oncology|July 2, 2014
Acquired resistance to TKIs in solid tumours: learning from lung cancerD Ross Camidge, William Pao, Lecia V Sequist
Plos One|November 5, 2015
Dose-Dependent Mutation Rates Determine Optimum Erlotinib Dosing Strategies for EGFR Mutant Non-Small Cell Lung Cancer PatientsLin L Liu, Fei Li, William Pao, et al.
Materials (Basel, Switzerland)|November 30, 2019
Erosion-Corrosion of 30°, 60°, and 90° Carbon Steel Elbows in a Multiphase Flow Containing Sand ParticlesRehan Khan, Hamdan H Ya, William Pao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2013
Epidermal growth factor receptor tyrosine kinase inhibitor-resistant diseaseKadoaki Ohashi, Yosef E Maruvka, Franziska Michor, et al.
Neoplasia (New York, N.Y.)|May 14, 2008
Constitutive activation of Raf-1 induces glioma formation in miceYelena Lyustikman, Hiroyuki Momota, William Pao, et al.
Journal of the National Cancer Institute|August 5, 2004
Predicting sensitivity of non-small-cell lung cancer to gefitinib: is there a role for P-Akt?William Pao, Vincent A Miller, Ennapadam Venkatraman, et al.
BMC Molecular Biology|October 1, 2003
A protein knockdown strategy to study the function of beta-catenin in tumorigenesisFeng Cong, Jianxuan Zhang, William Pao, et al.
Pageof 21

Showing results (31-40 of 202) with videos related to

Sort By:
Pageof 21
Genome Research|September 29, 2012
Translating genomic information into clinical medicine: lung cancer as a paradigmMia A Levy, Christine M Lovly, William Pao
Seminars in Cancer Biology|February 6, 2004
'Targeting' the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa) in non-small cell lung cancer (NSCLC)William Pao, Vincent A Miller, Mark G Kris
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 18, 2012
Effects of pharmacokinetic processes and varied dosing schedules on the dynamics of acquired resistance to erlotinib in EGFR-mutant lung cancerJasmine Foo, Juliann Chmielecki, William Pao, et al.
Nature Reviews. Clinical Oncology|July 2, 2014
Acquired resistance to TKIs in solid tumours: learning from lung cancerD Ross Camidge, William Pao, Lecia V Sequist
Plos One|November 5, 2015
Dose-Dependent Mutation Rates Determine Optimum Erlotinib Dosing Strategies for EGFR Mutant Non-Small Cell Lung Cancer PatientsLin L Liu, Fei Li, William Pao, et al.
Materials (Basel, Switzerland)|November 30, 2019
Erosion-Corrosion of 30°, 60°, and 90° Carbon Steel Elbows in a Multiphase Flow Containing Sand ParticlesRehan Khan, Hamdan H Ya, William Pao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2013
Epidermal growth factor receptor tyrosine kinase inhibitor-resistant diseaseKadoaki Ohashi, Yosef E Maruvka, Franziska Michor, et al.
Neoplasia (New York, N.Y.)|May 14, 2008
Constitutive activation of Raf-1 induces glioma formation in miceYelena Lyustikman, Hiroyuki Momota, William Pao, et al.
Journal of the National Cancer Institute|August 5, 2004
Predicting sensitivity of non-small-cell lung cancer to gefitinib: is there a role for P-Akt?William Pao, Vincent A Miller, Ennapadam Venkatraman, et al.
BMC Molecular Biology|October 1, 2003
A protein knockdown strategy to study the function of beta-catenin in tumorigenesisFeng Cong, Jianxuan Zhang, William Pao, et al.
Pageof 21